Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-10-13

FDA Approved: LITHIUM — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)

View source ↗

Summary

The FDA approved a supplemental application for Lithium from PAI Holdings (PAI Pharma) to an already approved drug, likely resulting in labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lithium (Lithium carbonate)

Snippet

SUPPL AP for LITHIUM (LITHIUM)